FDA Authorizes New COVID-19 Vaccine Without Clinical Data

“The U.S. Food and Drug Administration (FDA) has authorized a new COVID-19 vaccine from Novavax, giving Americans an alternative to shots from Moderna and Pfizer. Novavax’s protein-based vaccine will be available soon after regulators granted emergency authorization to the Maryland-based company for the product. FDA officials said that animal testing data supported the decision…Critics say that the agency should not be making an assertion about safety and effectiveness in the absence of clinical trial data.”

FDA Authorizes New COVID-19 Vaccine Without Clinical Data | The Epoch Times

Published by markskidmore

Mark Skidmore is Professor of Economics at Michigan State University where he holds the Morris Chair in State and Local Government Finance and Policy. His research focuses on topics in public finance, regional economics, and the economics of natural disasters. Mark created the Lighthouse Economics website and blog to share economic research and information relevant for navigating tumultuous times.

Leave a Reply

Discover more from Lighthouse Economics

Subscribe now to keep reading and get access to the full archive.

Continue reading